Abstract
OBJECTIVE: To review the literature for the management of insomnia. DATA SOURCE: MEDLINE/PUBMED searches (January 1950-June 2010) were conducted to identify pertinent English-language studies. STUDY SELECTION AND DATA EXTRACTION: All studies evaluating aspects of the treatment of insomnia. DATA SYNTHESIS: Insomnia is a major public health problem requiring effective diagnosis and treatment. Treatment options include cognitive behavioral therapy as well as pharmacologic therapy. Benzodiazepine receptor-agonist modulators are considered first-line therapy in the treatment of chronic insomnia. A nonbenzodiazepine receptor-modulator option to improve sleep latency is ramelteon. Low-dose sedative antidepressants, such as quetiapine or olanzapine, may be used in the treatment of comorbid insomnia. Over-the-counter and herbal agents are not recommended. CONCLUSION: Numerous medications being used in the management of insomnia have side effects that can limit their use and have a potential for drug interactions. Furthermore, some medications used in the treatment of insomnia do not have clinical trial data to support their use. Future studies are warranted to define second- and third-line agents in the management of insomnia.
| Original language | English |
|---|---|
| Pages (from-to) | 332-341 |
| Number of pages | 10 |
| Journal | Consultant Pharmacist |
| Volume | 26 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2011 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
Cite this
Insomnia : A therapeutic review for pharmacists. / Foral, Pamela; Dewan, Naresh; Malesker, Mark A.
In: Consultant Pharmacist, Vol. 26, No. 5, 05.2011, p. 332-341.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Insomnia
T2 - A therapeutic review for pharmacists
AU - Foral, Pamela
AU - Dewan, Naresh
AU - Malesker, Mark A.
PY - 2011/5
Y1 - 2011/5
N2 - OBJECTIVE: To review the literature for the management of insomnia. DATA SOURCE: MEDLINE/PUBMED searches (January 1950-June 2010) were conducted to identify pertinent English-language studies. STUDY SELECTION AND DATA EXTRACTION: All studies evaluating aspects of the treatment of insomnia. DATA SYNTHESIS: Insomnia is a major public health problem requiring effective diagnosis and treatment. Treatment options include cognitive behavioral therapy as well as pharmacologic therapy. Benzodiazepine receptor-agonist modulators are considered first-line therapy in the treatment of chronic insomnia. A nonbenzodiazepine receptor-modulator option to improve sleep latency is ramelteon. Low-dose sedative antidepressants, such as quetiapine or olanzapine, may be used in the treatment of comorbid insomnia. Over-the-counter and herbal agents are not recommended. CONCLUSION: Numerous medications being used in the management of insomnia have side effects that can limit their use and have a potential for drug interactions. Furthermore, some medications used in the treatment of insomnia do not have clinical trial data to support their use. Future studies are warranted to define second- and third-line agents in the management of insomnia.
AB - OBJECTIVE: To review the literature for the management of insomnia. DATA SOURCE: MEDLINE/PUBMED searches (January 1950-June 2010) were conducted to identify pertinent English-language studies. STUDY SELECTION AND DATA EXTRACTION: All studies evaluating aspects of the treatment of insomnia. DATA SYNTHESIS: Insomnia is a major public health problem requiring effective diagnosis and treatment. Treatment options include cognitive behavioral therapy as well as pharmacologic therapy. Benzodiazepine receptor-agonist modulators are considered first-line therapy in the treatment of chronic insomnia. A nonbenzodiazepine receptor-modulator option to improve sleep latency is ramelteon. Low-dose sedative antidepressants, such as quetiapine or olanzapine, may be used in the treatment of comorbid insomnia. Over-the-counter and herbal agents are not recommended. CONCLUSION: Numerous medications being used in the management of insomnia have side effects that can limit their use and have a potential for drug interactions. Furthermore, some medications used in the treatment of insomnia do not have clinical trial data to support their use. Future studies are warranted to define second- and third-line agents in the management of insomnia.
UR - http://www.scopus.com/inward/record.url?scp=80051556411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051556411&partnerID=8YFLogxK
U2 - 10.4140/TCP.n.2011.332
DO - 10.4140/TCP.n.2011.332
M3 - Review article
C2 - 21733814
AN - SCOPUS:80051556411
VL - 26
SP - 332
EP - 341
JO - The Senior care pharmacist
JF - The Senior care pharmacist
SN - 2639-9636
IS - 5
ER -